Evidence map›Paper›PMID 24717098›Full record

ArticleMolecular pharmaceutics2014

A radiofluorinated divalent cystine knot peptide for tumor PET imaging.

Lei Jiang, Richard H Kimura, Xiaowei Ma, Yingfeng Tu, Zheng Miao, Bin Shen, Frederick T Chin, Hongcheng Shi, Sanjiv Sam Gambhir, Zhen Cheng

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Cyclotides: Overview and Biotechnological Applications.Chembiochem : a European journal of chemical biology · 2017
    Review
  3. Core-shell NaGdFScientific reports · 2017
    Article
  4. Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis.Annual review of analytical chemistry (Palo Alto, Calif.) · 2017
    Review
  5. Plant cystine-knot peptides: pharmacological perspectives.British journal of clinical pharmacology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lei JiangDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University , 180 Fenglin Road, Shanghai, China 200032.
Richard H Kimura
Xiaowei Ma
Yingfeng Tu
Zheng Miao
Bin Shen
Frederick T Chin
Hongcheng Shi
Sanjiv Sam Gambhir
Zhen Cheng

Funding

Small Animal ImagingP50CA114747 · NCI · STANFORD UNIVERSITY · PI RAO, JIANGHONG · 2005 to 2014
$18.2M
NCI NIH HHS P50 CA114747NCI NIH HHS P50CA114747
6 · The paper itself

Abstract

A divalent knottin containing two separate integrin binding epitopes (RGD) in the adjacent loops, 3-4A, was recently developed and reported in our previous publication. In the current study, 3-4A was radiofluorinated with a 4-nitrophenyl 2-(18)F-fluoropropinate ((18)F-NFP) group and the resulting divalent positron emission tomography (PET) probe, (18)F-FP-3-4A, was evaluated as a novel imaging probe to detect integrin αvβ3 positive tumors in living animals. Knottin 3-4A was synthesized by solid phase peptide synthesis, folded, and site-specifically conjugated with (18/19)F-NFP to produce the fluorinated peptide (18/19)F-fluoropropinate-3-4A ((18/19)F-FP-3-4A). The stability of (18)F-FP-3-4A was tested in both phosphate buffered saline (PBS) buffer and mouse serum. Cell uptake assays of the radiolabeled peptides were performed using U87MG cells. In addition, small animal PET imaging and biodistribution studies of (18)F-FP-3-4A were performed in U87MG tumor-bearing mice. The receptor targeting specificity of the radiolabeled peptide was also verified by coinjecting the probe with a blocking peptide cyclo(RGDyK). Our study showed that (18)F-FP-3-4A exhibited excellent stability in PBS buffer (pH 7.4) and mouse serum. Small animal PET imaging and biodistribution data revealed that (18)F-FP-3-4A exhibited rapid and good tumor uptake (3.76 ± 0.59% ID/g and 2.22 ± 0.62% ID/g at 0.5 and 1 h, respectively). (18)F-FP-3-4A was rapidly cleared from the normal tissues, resulting in excellent tumor-to-normal tissue contrasts. For example, liver uptake was only 0.39 ± 0.07% ID/g and the tumor to liver ratio was 5.69 at 1 h p.i. Furthermore, coinjection of cyclo(RGDyK) with (18)F-FP-3-4A significantly inhibited tumor uptake (0.41 ± 0.12 vs 1.02 ± 0.19% ID/g at 2.5 h) in U87MG xenograft models, demonstrating specific accumulation of the probe in the tumor. In summary, the divalent probe (18)F-FP-3-4A is characterized by rapid and high tumor uptake and excellent tumor-to-normal tissue ratios. (18)F-FP-3-4A is a highly promising knottin based PET probe for translating into clinical imaging of tumor angiogenesis.

Indexed as

Positron-Emission TomographyAmino Acid MotifsAmino Acid SequenceAnimalsCell Line, TumorChromatography, High Pressure LiquidCysteineCystine-Knot MiniproteinsEpitopesFemaleFluorine RadioisotopesHumansHydrogen-Ion ConcentrationInhibitory Concentration 50Integrin alphaVbeta3Liverarginyl-glycyl-aspartic acidCysteineCystine-Knot MiniproteinsEpitopesFluorine RadioisotopesIntegrin alphaVbeta3OligopeptidesPeptidesProtease InhibitorsTrypsin18Fcystine-knot peptidedivalentintegrin αvβ3PET

Identifiers

PMID24717098
PMCPMC4212002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.